Literature DB >> 24645769

Current perspectives on HIV-related pain and its management: insights from sub-Saharan Africa.

Peter R Kamerman1, Duncan Mitchell.   

Abstract

SUMMARY Sub-Saharan Africa is the region worst affected by the HIV epidemic and we estimate that at least 10 million HIV-positive individuals in sub-Saharan Africa live with significant pain related to their disease. Until recently there was a lack of studies specifically addressing pain related to HIV infection in sub-Saharan Africa, which limited our understanding of the scope of the problem. Here we describe the current nature of the epidemic of HIV-related pain in sub-Saharan Africa, including the systematic under-recognition and undertreatment of the pain.

Entities:  

Year:  2011        PMID: 24645769     DOI: 10.2217/pmt.11.65

Source DB:  PubMed          Journal:  Pain Manag        ISSN: 1758-1869


  5 in total

Review 1.  HIV-associated sensory neuropathy: risk factors and genetics.

Authors:  Peter R Kamerman; Antonia L Wadley; Catherine L Cherry
Journal:  Curr Pain Headache Rep       Date:  2012-06

2.  An innovative approach to reducing pain in patients with peripheral neuropathy related to HIV: A single case study.

Authors:  Natalie A Benjamin; Jennifer Jelsma
Journal:  Afr J Disabil       Date:  2014-08-07

3.  Pain in amaXhosa women living with HIV/AIDS: a cross-sectional study of ambulant outpatients.

Authors:  Romy Parker; Jennifer Jelsma; Dan J Stein
Journal:  BMC Womens Health       Date:  2017-04-13       Impact factor: 2.809

4.  Managing pain in HIV/AIDS: a therapeutic relationship is as effective as an exercise and education intervention for rural amaXhosa women in South Africa.

Authors:  Kirsty Jackson; Antonia L Wadley; Romy Parker
Journal:  BMC Public Health       Date:  2021-02-05       Impact factor: 3.295

5.  Resilience does not explain the dissociation between chronic pain and physical activity in South Africans living with HIV.

Authors:  Antonia L Wadley; Duncan Mitchell; Peter R Kamerman
Journal:  PeerJ       Date:  2016-09-13       Impact factor: 2.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.